Upadacitinib treatment patterns, achievement of treatment targets and maintenance of response in moderate to severe Rheumatoid Arthritis patients in real-world practice (UPHOLD).
Year: 2020
Type: Musculoskeletal
Phase: Post-Market
Indication: Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis.
Year: 2021
Type: Musculoskeletal
Phase: IIIb, IV
Indication: Rheumatoid Arthritis
A Phase 3b/4 Randomized Double-Blind Placebo Controlled Study Of Methotrexate (Mtx) Withdrawal In Subjects With Rheumatoid Arthritis (Ra) Treated With Tofacitinib 11mg Modified Release (Mr) Formulation.
Year: 2017
Type: Musculoskeletal
Phase: IIIb, IV
Indication: Rheumatoid Arthritis
A 12 Week Randomized, Double-Blind, Double Dummy, Parallel Group, Active And Placebo-Controlled, Multicenter Study To Assess The Efficacy And Safety Profile Of Pf-06650833 In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To Methotrexate.
Year: 2017
Type: Musculoskeletal
Phase: II
Indication: Rheumatoid Arthritis
Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Participants with Active Rheumatoid Arthritis despite Ongoing Methotrexate Therapy.
Year: 2010
Type: Musculoskeletal
Phase: II
Indication: Rheumatoid Arthritis
A Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patients with or At High Risk for Cardiovascular Disease Comparing Celecoxib with Naproxen and Ibuprofen.
